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Summary A monoclonal antibody (L.1), reacting in vitro specifically with L1210 leukaemia cells in a
complement-dependent cyctotoxicity assay (CDC), has been exploited for serotherapy studies. Different
regimens of L.1 treatment of CD2F1 mice bearing the semi-syngeneic L1210 leukaemia did not prolong the life
span of tumor-bearing animals. Moreover, the administration of L.1 did not enhance the antitumour effects
of cyclophosphamide. Studies of in vivo localization showed that L.1 was able to bind specifically to L1210
leukaemic cells, although 30-40% of the cells remained negative. The presence of L.1 in mouse blood was
demonstrated up to 15 days after the inoculation. On the other hand, in vivo administration of L.1 was
probably accompanied by loss of the cytotoxic activity, perhaps through a mechanism of complement
inactivation, since the presence of undiluted normal mouse serum in a CDC assay inhibited the cytotoxic
activity of L.1. Moreover, serum from L.1-treated mice did not display any cytotoxic activity, although the
presence of the antibody could be demonstrated by indirect immunofluorescence.
Shedding of the antigen defined by L.1 was probably not responsible for the failure of the serotherapy,
since the L. 1 neutralizing antigen could be found in body fluids only long after the start of therapy.
The treatment of malignant diseases by passive
administration of antibodies (Wright & Bernstein
1980) has been pursued as a promising therapy,
although the life span after antiserum
administration has not so far been improved. The
failure of conventional serotherapy has been mainly
attributed to the low specificity of the antisera and
the poor immunogenicity of tumour-associated
antigens (TAA). The new era in serology since
hybridoma technology (Kohler & Milstein 1975)
was devised might be exploited for new modalities
of cancer immunotherapy.
Tumour-specific antigens and specific antibodies
are the basic necessities for successful passive
immunotherapy of cancer. Although tumour-
specific antigens in human tumours (Metzgar et al.,
1981; Iwaki et al., 1982; Ball et al., 1982) have not
yet been definitely demonstrated, monoclonal
antibodies (MAb) highly specific to TAA (Gunn et
al., 1981) or to tissue and differentiation antigens
(Kirch & Hammerling, 1981) might provide optimal
tools to study the anti-tumour efficacy of passive
serotherapy (Kirch & Hammerling, 1981; Bernstein
et al., 1980; 1980; Scheinberg & Strand 1982; Ritz
et al., 1981; Trowbridge & Lopez, 1982; Sears et al.,
1982).
In a previous report from this laboratory
(Testorelli et al., 1982), the production and the
characterization of a MAb reacting specifically with
the cells of the L1210 murine leukaemia (L.1) was
described. The L.1 MAb displayed in vitro very
high and specific complement-dependent
cytotoxicity against L1210 cells. On the other hand,
it did not react with normal adult and foetal
murine tissues, with cells from several independent
haplotypes or with a number of chemical- and
virus-induced experimental tumours.
In the present report, the therapeutic effects of
the administration of L.1 alone or combined with
chemotherapeutic agents on the survival rates of
leukaemic mice are presented. Possible reasons for
the ineffectiveness of serotherapy with L.1 were
also investigated and are discussed.
Materials and methods
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Animals and tumours
Inbred DBA/2, Balb/c and hybrid (Balb/c x DBA/2)
CD2F1 male mice, 10-15 weeks old, were obtained
from Charles River (Calco, Italy). L1210/Cr
leukaemia was maintained by weekly passages (i.p.)
into compatible CD2F1 mice. Balb/c or CD2F1
(J The Macmillan Press Ltd., 1983354 C. TESTORELLI et al.
mice were used to produce antibody-containing
ascites.
Hybrid cell lines andproduction ofasciticfluid
The production of the hybridoma cell line secreting
the monoclonal antibody L.1 (IgM) to a surface
antigen of L1210 cells has been described
previously (Testorelli et al., 1982). The hybridoma
was maintained in culture in RPMI 1640 medium
(Eurobio, Paris), supplemented with 10% heat-
inactivated foetal calf serum (FCS, Seromed GmBg,
Miinchen, Germany) and lOO1 Iml- gentamycin
(Seromed). The supernatant from the cultures was
stored at -70°C. For production of ascitic fluid,
Balb/c or CD2F, mice, preprimed with pristane
(0.5ml,i.p.), were injected i.p. with 106 hybrid cells.
Ascitic fluid was collected after 15-20 days,
centrifuged to remove the cells and frozen at
-70"C until use. The cytotoxic titers of both
supernatant and ascitic fluid were assessed by a
complement-dependent cytotoxicity assay (see
below) using Cr-labelled L1210 cells as target.
Titres are expressed as the highest dilution that
killed 50% of leukaemic cells. When not otherwise
specified, the cytotoxic titre was 1:64 for the
supernatant from the hybridoma culture and 10-6
for ascites.
Complement-dependent cytotoxicity assay (CDC)
51Cr-release assay was performed as described
elsewhere (Testorelli et al., 1982). Briefly, 25,l of
target cells labelled with [51Cr] sodium chromate
were incubated with 25jl of the L.1 (P3X63/Ag8
supernatant was used as control) for 45 min at
37°C. Rabbit complement diluted 1:5 was then
added (25,l) and the cells were incubated for
30min at 37°C in a humidified 5% CO2
atmosphere. The percentage of Cr release into the
supernatants of triplicate samples was calculated
according to Ozato et al. (Ozato et al., 1980).
Indirect membrane immunofluorescence (IMF)
The L1210 cells were tested after extensive washing
for their viability (cells <95% viable were
excluded) and incubated with 20,l of supernatant
from the hybridoma culture for 40min at 4 C. The
cells were washed twice and subsequently incubated
with 0.15 of a 1:10 dilution of fluorescein
isothiocyanate-conjugated (FITC) rabbit anti-mouse
IgG (Cappel Lab., Cochranville, PA) for 30min at
4°C. The cells were washed 3 x and analyzed under
a microscope with epifluorescence optics and in the
fluorescence-activated cell sorter (FACS II, Becton
Dickinson, Mountain View, Calif.).
Serotherapy ofL]210-bearing mice with L.J
CD2F1 were challenged i.p. with different numbers
of L1210 cells (day 0). Experimental animals were
given injections of L.I (ascitic fluid containing
30mg MAbml-1) alone or combined with rabbit
complement, starting 24h after challenge. Different
schedules of treatment were adopted. In the
combined therapy, L.1 was given i.p. with
cyclophosphamide 120mgkg-1 s.c. Tumour growth
was evaluated by recording the median survival
time (MST) and the number of dead animals per
group (D/T) of control and treated animals.
In vitro evaluation ofserotherapj'
In vivo binding of L.] to L1210 At different
intervals after the i.v. infusion of L.1 into L1210-
bearing mice, tumour cells were collected from
peritoneal cavity and divided into 2 pools. The first
pool was analysed by IMF for the presence of L.1
on the cells surface. The cells from the second pool
were labelled with 5Cr and assayed for their
susceptibility to lysis by the CDC system.
Detection of L.J in the serum of normal
mice Blood samples from CD2F, mice infused i.v.
with L.1 were collected at different times after the
injection and the serum tested for the presence of
L.I by both the IMF and CDC systems.
Detection of circulating antigen in L1210 mouse
fluids The presence of the antigen defined by L.1
in the serum and in the ascites of L1210-bearing
mice was detected by incubating at 4°C for 45min
an appropriate dilution of L. 1 (supernatant from
hydridoma culture) with an equal volume of serum
or ascites (undiluted, 1:2, 1:4 etc.) from mice at
different days after tumour challenge. The resulting
L. 1 cytotoxic activity was assayed against L1210
target cells.
Inhibition of complement activity by normal mouse
serum Normal sera from different strains of mice
were mixed for 45min at 4°C with 5Cr-labelled
L1210 cells (106) and L.1 culture supernatant. The
mixture (50,ul) was seeded in a 96-well microplate,
complement was added (25pl) and the cytotoxic
activity of L. 1 was evaluated as reported above
(CDC).
Results
Effects of L.] administration on survival of
leukaemic mice
The results of passive serotherapy of leukaemic
mice with L.I and rabbit serum, as source ofSEROTHERAPY OF MURINE LEUKAEMIA BY MONOCLIONAL ANTIBODIES
Table I Serotherapy of L1210-leukaemic CD2F1 mice with L.1 and complement
Rabbit
L.la complementb
L1210 Day+ I Day+ I MSTC
Challenge, i.p. ml/mouse, i.p. ml/mouse, i.p. (range) D/Td
103* 12(11-14) 8/8
103* 1.0 13(11-14) 8/8
103* 0.4 13(12-14) 8/8
103* 0.01 0.4 13(12-14) 8/8
103* 0.1 0.4 12(12-13) 8/8
103* 1.0 0.4 12(12-14) 8/8
aThe source of L.1 was an ascitic fluid containing 30mg antibodyml with a
cytotoxic titre of 10-6.
bComplement activity was checked in vitro.
cMST: Median Survival Time (days).
dD/T: Dead Mice/Treated Mice.
*The same treatment to mice challenged with 105 L1210 cells was ineffective.
complement, are reported in Tables I and II. The
life spans of CD2F1 mice, challenged with as few as
103 L1210 cells, was not improved by treatment
with different amounts of L.1 plus 0.4ml of
complement. No increase in survival time of
leukaemic mice was obtained with the treatment
schedules in Table II, either. In order to see
Table II Serotherapy of L1210-leukaemic CD2F1 mice
with L.1 and complement
L.la
Days and route
L1210 of treatment MST
Challenge i.p. 0.5ml/mouse (Range) D/T
103* _ 13(12-13) 8/8
103* 1 3,5 i.p. 14(11-15) 8/8
103* 1,3,5i.v. 12(11-13) 8/8
103* 1-7i.p. 14(13-15) 8/8
103* 1-7i.v. 14(12-15) 8/8
aSee Table I. Rabbit serum as source of complement
(0.4ml/mouse, i.p.) was given after every LA1 inoculation.
*The same treatment in mice challenged with 105 L1210
cells was ineffective.
whether the MAb acted synergistically with a
chemotherapeutic agent, leukaemic mice were
treated with an effective dose of cyclophosphamide
plus L.1. As shown in Table III serotherapy did not
significantly increase the survival time over
cyclophosphamide alone.
L.1 binding to L1210 cells in vivo
In order to study the reasons for the failure of L.1
therapy, experiments were designed to determine
whether the L. 1 could bind specifically to tumour
cells in vivo. Figure shows that, although 24h
after L. administration the majority of Ll210 cells
were stained, a remarkable proportion of unstained
cells was still detectable. Moreover, the fluorescence
intensity of stained cells was never >20% of that
of L1210 cells treated in vitro with L.1. The % of
+ ve cells and fluorescence intensity were
completely restored when Ll210 cells interacting
with L. in vivo were further exposed to the MAb
in vitro.
Results of time-course experiments are also
illustrated in Figure 1. The % of L. 1 + ve cells
analysed by automatic flow fluorocytometry peaked
Table III Chemotherapy plus serotherapy of L1210-leukaemic CD2F1 mice
L1210 Cya L.lb
Day 0 Day+J Day+2 MST
Challenge i.p. 120mgKg- s.c. 0.5ml/mouse i.v. (Range) D/T
l05 9(8-10) 8/8
l05 + _ 12(11-14) 8/8
105 - + 10( 9-10) 8/8
105 + + 11(10-13) 8/8
aCyclophosphamide. bL.1 and rabbit complement; see footnote Table II.
355356 C. TESTORELLI et al.
tS 80_- .
g60 :
cn~~~~~~~~~~~~~~~~~~~~I
C
<> 40,-< _ 5O0
o
20 s--t----- ,
2 4 6
Time (d) after Li infusion
Figure 1 Binding of L.l to L1210 cells in vivo. L1210
leukaemic cells, obtained from tumour-bearing animals
at different intervals from an i.v. administration of L.I
(0.2ml of ascites diluted 1:4) were analyzed for the
presence of the MAb on their surface by IMF. The
fluorescence staining ( ) and the fluorescence
intensity (----) of L1210 leukaemic cells treated in vivo
with L.1 (0) and further exposed to L.1 in vitro (0)
are reported. Tumour cells from untreated animals
were used as -ve controls.
24h after the L. 1 inoculation and decreased
gradually, although 15% of +ve cells were still
detected 6 days after the treatment. As shown in
Table IV, the amount of L.1 bound to L1210 cells
after in vivo treatment was dependent upon the
dose of the antibody injected. Findings in keeping
with those reported in Figure 1 were obtained in
the cytotoxic assay. (Figure 2). A % of tumour
cells derived from L1210-bearing mice previously
treated with L.1 underwent lysis upon in vitro
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Figure 2 In vitro lysis of L1210 cells treated in vivo
with L.I. The in vivo treatment was performed as
reported in Figure 1. L1210 tumour cells collected
from L.I treated mice were labelled with slCr and
assayed in the CDC assay in the presence of rabbit
complement alone (0) and after further exposure to
L.1 in vitro (0) (supernatant from culture). Controls
were performed using L1210 cells from untreated mice
incubated in vitro with rabbit complement alone (x)
or with L.1 + complement (*).
incubation- with rabbit complement. However, full
susceptibility to complement-mediated lysis was
obtained upon cell re-exposure to L. I in vitro.
Studies of L.I properties after in vivo
administration
The time course of blood L.1 levels in CD2F1 mice,
as evaluated by IMF (dashed line) or by the 51Cr-
release assay (full line), was studied (Figure 3).
look
Table IV Binding of L.l to L1210 cells in vivo; dose-
response relationship
L.lb Fluorescence Dye Test
antibody % stained %dead
dilution cellsa cellsa
- 33+0.1 9+0.3
100 64+6.9 78+0.8
10-1 67+6.2 75+2.5
10-2 34+7.6 33+ 1.3
10-3 18+4.1 24+0.9
10-4 6+0.3 19+0.1
'Mean +s.e..
bTumour-bearing mice were infused i.v. with L.1
(ascites, 0.5ml/mouse) and, 24h later, L1210 leukaemic
cells were collected and assayed for the presence of L. I by
IMF and by the Dye exclusion test of Gorer & O'Gorman
(1956).
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Figure 3 Blood kinetics of L.1 in CD2F1 mice.
Serum samples from CD2F, mice i.v. infused with 1 ml
of L.1 (0.2ml of ascites diluted 1:4) were analyzed for
the presence of the MAb in the IMF (l----l) and
CDC (0 0) assays at different times after
inoculation.
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L1210 cells incubated with serum from L.1 treated
mice were stained positively in the IMF assay.
After 4 days, the binding activity dropped
progressively, although it was still detectable 15
days after L. 1 inoculation. In sharp contrast, no
cytotoxic activity was present in serum from L.1-
treated mice. The possibility that complement
inactivation by mouse serum was responsible for
the in vivo loss of L.1 cytotoxic activity, was
investigated. Serum samples from CD2F1 mice
inoculated i.v. with rabbit complement did not
show any complement activity in the CDC (data
not shown). Moreover, the presence of undiluted
mouse serum in the CDC assay inhibited the
cytotoxic reaction, whatever the source of
complement (Table V). However, a normal lytic
reaction was observed when the mouse serum was
removed before the addition of complement.
L1210 antigen in mousefluids
The detectability of antigen recognized by L.1 shed
by tumour cells into the blood or the ascites of
Table V Inhibition of complement activity by normal
mouse serum
Serumfrom Source of % 51Cr
mouse strain complement* cpm+s.e. release
rabbit 2495+207 80.3
CD2F1 rabbit 430+ 38 0.2
CD2F1 rabbit 426+ 41 0
CD2F1 rabbit 448 + 39 0
CD2F1 guinea pig 428 + 46 0
CD2F1 guinea pig 431 + 37 0.2
CD2F1 human 445 + 48 0.8
DBA/2 rabbit 412+ 40 0
Balb/c rabbit 429+ 45 0
C57B1/6 rabbit 410+ 28 0
C3H/f rabbit 425+ 33 0
CD2F1 (w) rabbit 2360+250 75.5
CD2FS(w) guinea pig 2405±+198 77.2
CD2F,(w) human 2381 +279 76.3
The cytotoxic activity of L.1 was evaluated in a CDC
with L1210 target cells, in the presence of normal serum
from different strains of mice as described in Materials
and Methods. When indicated (w), L.1 and mouse serum
were washed off before adding the complement. L.1
(supernatant from hybridoma culture) was present in all
samples. Replacement of L.1 with rabbit anti mouse
serum caused similar results.
*Sources of rabbit complement were selected from non-
cytotoxic blood samples from our breeding colony.
Guinea pig sources were purchased (Bio Mrieux,
France). Human complement was from healthy donors.
All samples were assayed in vitro for complement activity
before use, and for each complement the appropriate
dilution was selected. This Table uses rabbit complement
as a +ve control.
L1210-bearing mice was examined. Inhibition of
cytotoxic activity of L.1 by serum and ascites fluid
from leukaemic mice obtained at varying intervals
after the challenge is reported in Figure 4. The
inhibitory capacity of mouse fluids, not detectable
until 4 days after the tumour inoculation, increased
rapidly thereafter and was more impressive for the
ascites fluid than for the serum. Titration of soluble
antigen (Figure 5) showed that a relatively large
amount of free antigen was detectable in the ascites
fluid on day 7, whereas a lesser degree of inhibitory
activity was demonstrable on day 5.
100 _
0~~~~~~~~~~
C I
. 50
/ /
2 4 6 8 10
Time (d) after L1210 challenge
Figure 4 Inhibition of the cytotoxic activity of L.1 by
ascites and serum from L1210-bearing mice. The
supernatant from the hybridoma culture was incubated
at 4°C for 45 min with the serum (*-@) and the
ascites (@----@) from L1210-bearing mice on different
days after the challenge i.p. with 104 leukaemic cells.
The mixture was added to L1210-labelled cells and
incubated at 37°C (45min). After washing an
appropriate dilution of complement was added as
described for the CDC assay. The results are expressed
as % inhibition of L.1 cytotoxicy.
Discussion
In principle, specific and cytotoxic MAb should
provide selective bullets for the in vivo eradication
of cancerous cells leaving normal cells undamaged.
These theoretical conditions, hypothesized since the
Ehrlich era, were obtained in our laboratory by the
production of L.1. In fact, L.1 is absolutely specific
to L1210 leukaemic cells and as an IgM
immunoglobulin displays great efficiency in fixing
complement (Testorelli et al., 1982). Furthermore,
since the CD2F1 mice used in these studies were of358 C. TESTORELLI et al.
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Figure 5 Inhibition of the cytotoxic activity of L.1 by
cell-free ascites from L1210-bearing mice. Varying
dilutions of cell-free ascites from L1210-bearing mice
challenged i.p. with 104 leukaemic cells were incubated
at 4°C for 45min with the supernatant from the
hybridoma culture. The residual cytotoxic activity of
L.1 was determined in a CDC assay as reported in
Figure 4. The inhibitory activity of the ascites
obtained on Day 5 (0-0) and on Day 7 (x----x)
after the L1210 challenge is illustrated.
identical haplotype to that of the L.1 hybridoma
cells, strictly syngeneic conditions could be
obtained. However, even under these optimal
theoretical conditions, L.1 serotherapy was almost
completely ineffective in increasing the survival time
of L1210-bearing CD2F1 mice. Variations of the
schedule of route or treatment, of the amounts of
antibody or of complement were consistently
unsuccessful. One reasonable cause for failure, the
low level of endogenous complement in mice, was
counteracted by excessive inoculation of exogenous
complement, but this manoevre was without
improvement. Since the activation of an
endogenous immune response (Kirch &
Hammerling, 1981) is a possible effector mechanism
of serotherapy, L.1 might synergize with an
effective antitumour drug. Following this line, a
number of treatments with cyclophosphamide or
with other anticancer compounds (not reported
here) were combined with L.1 serotherapy, without
any additional increase in the life-span of the
mouse.
To account for the failure of L.1 serotherapy
several experiments were devised. The first set was
conceived to see whether or not L. 1 given i.v. to
tumour-bearing mice bound to peritoneal L1210
cells. Although the results were positive (Figure 1) a
lower percentage than expected of dead cells and of
fluorescent cells was regularly observed. It is
noteworthy that the fluorescence intensity of in vivo
L.1-treated cells was 80% below the intensity
achieved in the in vitro-treated control cells.
Decreased susceptibility to in vitro complement-
mediated lysis by L1210 cells exposed in vivo to L.1
was confirmed by the 5'Cr-release assay. Finally,
we found that the susceptibility to both
complement-mediated lysis and to staining with a
second antibody were completely restored after in
vitro re-exposure to L.1.
The in vivo studies suggest the following
conclusions: (a) a fraction of L1210 cells did not
bind L.1 in vivo; (b) the amount of L.1 bound to
the surface cells +ve by IMF-was less than for in
vitro-treated controls, as demonstrated by the lower
fluorescence intensity; (c) the in vivo L.1 +ve cells,
in spite of their low fluorescence intensity, were still
susceptible to in vitro lysis in presence of an
appropriate source of complement; (d) the antigenic
specificity defined by L.I did not undergo
modulation, since fluorescence intensity and
susceptibility to lysis were fully recovered after in
vitro re-exposure to L.1: (e) cells -ve by IMF and
those resistant to complement-mediated lysis might
belong to the same subpopulation.
Although blood clearance of L.1 in the mouse
had the half life already described by others for the
same antibody class (Bernstein et al., 1980; Kirch &
Hammerling 1981), blood serum samples containing
L.1 and complement did not lyse L1210 cells in
vitro. Furthermore, complement from different
sources mixed with mouse serum in vitro was
completely inactivated.
Antigen shedding cannot be responsible for the
failure of L.1 serotherapy since, at the start of
serotherapy, soluble antigen was not found in body
fluids. L.1 inhibition by mouse serum and even
more by ascites fluid from tumour-bearing mice
became evident 4 days after L1210 challenge.
Therefore, circulating antigen might negatively
influence late treatments only.
The experimental system used in these studies
although adhering to optimal theoretical conditions,
did not bring about increased survival time for
leukaemic mice. Incomplete antibody binding to
target cells and blood inactivation of complement
might be major factors in these disappointing
results.
A number of claims (Kirch & Hammerling, 1981;
Bernstein et al., 1980; Scheinberg & Strand 1982;
Miller & Levy, 1981; Ritz et al., 1980; Trowbridge
& Lopez 1982; Herlyn & Koprowski, 1981), of
therapeutic benefit from the use of MAb in cancer
therapy have been reported recently in the
literature. Partial successes in tumour systems other
than that used here could be attributed to different
Ig isotypes, acting through an antibody-dependentSEROTHERAPY OF MURINE LEUKAEMIA BY MONOCLONAL ANTIBODIES 359
cellular cytotoxicity (ADCC) rather than
complement-mediated lysis. The limited
achievements of this approach might result in
greater efforts (Pimm et al., 1982; Raso et al., 1982)
to exploit monoclonal technology to carry toxic
compounds specifically to their target cells.
Research supported in part by PFCCN, C.N.R., Rome,
Italy.
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